III期-话题@MedSci

#III期#

681篇内容 | 2801人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1594707, encodeId=70bc1594e07f5, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=JAK抑制剂baricitinib在III期特应性皮炎研究中显著改善皮肤炎症, objectType=article, longId=186909, objectId=12e1186909d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12e1186909d9, replyNumber=0, likeNumber=66, createdTime=2020-01-30, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12e1186909d9, moduleTitle=JAK抑制剂baricitinib在III期特应性皮炎研究中显著改善皮肤炎症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12e1186909d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594706, encodeId=00041594e0614, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=卡泊三醇喷雾剂治疗牛皮癣的III期临床取得阳性结果, objectType=article, longId=186746, objectId=f965186e4626, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f965186e4626, replyNumber=0, likeNumber=66, createdTime=2020-01-27, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f965186e4626, moduleTitle=卡泊三醇喷雾剂治疗牛皮癣的III期临床取得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f965186e4626)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594705, encodeId=4eab1594e0551, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=难治性晚期或复发性卵巢癌患者的III期试验：Opdivo（Nivolumab）未能改善总生存率, objectType=article, longId=186740, objectId=76ac186e40ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76ac186e40ac, replyNumber=0, likeNumber=84, createdTime=2020-01-27, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76ac186e40ac, moduleTitle=难治性晚期或复发性卵巢癌患者的III期试验：Opdivo（Nivolumab）未能改善总生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76ac186e40ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594704, encodeId=a8561594e04d9, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=传染性软疣的治疗：VP-102的III期CAMP试验取得阳性结果, objectType=article, longId=186578, objectId=36f11865e8b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36f11865e8b3, replyNumber=0, likeNumber=59, createdTime=2020-01-21, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36f11865e8b3, moduleTitle=传染性软疣的治疗：VP-102的III期CAMP试验取得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36f11865e8b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594703, encodeId=5a311594e03f9, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=礼来宣布以11亿美元收购Dermira，同时获得中度至重度特应性皮炎III期IL-13单抗lebrikizumab, objectType=article, longId=186390, objectId=85b418639058, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85b418639058, replyNumber=0, likeNumber=72, createdTime=2020-01-18, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85b418639058, moduleTitle=礼来宣布以11亿美元收购Dermira，同时获得中度至重度特应性皮炎III期IL-13单抗lebrikizumab, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85b418639058)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594702, encodeId=50481594e027d, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=NEJM的：诺华的IgE单抗Ligelizumab在慢性自发性荨麻疹的III期临床中完胜奥马珠单抗, objectType=article, longId=186027, objectId=868418602e8e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=868418602e8e, replyNumber=0, likeNumber=18, createdTime=2020-01-11, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=868418602e8e, moduleTitle=NEJM的：诺华的IgE单抗Ligelizumab在慢性自发性荨麻疹的III期临床中完胜奥马珠单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=868418602e8e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594701, encodeId=1ab71594e0129, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Apellis的C3补体抑制剂Pegcetacoplan用于阵发性夜间血红蛋白尿的III期临床成功, objectType=article, longId=185945, objectId=1f6e1859452d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f6e1859452d, replyNumber=0, likeNumber=14, createdTime=2020-01-10, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f6e1859452d, moduleTitle=Apellis的C3补体抑制剂Pegcetacoplan用于阵发性夜间血红蛋白尿的III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f6e1859452d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594700, encodeId=00841594e002a, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=默沙东的Keytruda治疗小细胞肺癌的III期临床，未能明显改善患者的总体生存率, objectType=article, longId=185921, objectId=fcce18592178, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcce18592178, replyNumber=0, likeNumber=95, createdTime=2020-01-10, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcce18592178, moduleTitle=默沙东的Keytruda治疗小细胞肺癌的III期临床，未能明显改善患者的总体生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcce18592178)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594699, encodeId=ce5e159469955, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=默克和辉瑞的抗PD-L1单抗Bavencio改善了局部晚期或转移性尿路上皮癌患者的生存率：III期临床达到主要终点, objectType=article, longId=185843, objectId=5f5518584350, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f5518584350, replyNumber=0, likeNumber=12, createdTime=2020-01-08, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f5518584350, moduleTitle=默克和辉瑞的抗PD-L1单抗Bavencio改善了局部晚期或转移性尿路上皮癌患者的生存率：III期临床达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f5518584350)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594698, encodeId=23661594698cc, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=J Clin Oncol：III期试验：Ipilimumab辅助疗法与大剂量干扰素α-2b用于高风险黑色素瘤的优劣对比, objectType=article, longId=185702, objectId=43a9185e0237, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43a9185e0237, replyNumber=0, likeNumber=16, createdTime=2020-01-06, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43a9185e0237, moduleTitle=J Clin Oncol：III期试验：Ipilimumab辅助疗法与大剂量干扰素α-2b用于高风险黑色素瘤的优劣对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43a9185e0237)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594697, encodeId=f18e159469eaa, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=J Clin Oncol：III期试验：培美曲塞联合贝伐单抗作为NSCLC患者的维持疗法的有效性和安全性, objectType=article, longId=185701, objectId=ca92185e013a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ca92185e013a, replyNumber=0, likeNumber=59, createdTime=2020-01-06, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ca92185e013a, moduleTitle=J Clin Oncol：III期试验：培美曲塞联合贝伐单抗作为NSCLC患者的维持疗法的有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ca92185e013a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594696, encodeId=12a41594696c8, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=国产肝癌创新药多纳非尼一线治疗晚期肝细胞癌III期临床研究获得成功, objectType=article, longId=185534, objectId=9c1618553426, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c1618553426, replyNumber=0, likeNumber=70, createdTime=2020-01-03, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c1618553426, moduleTitle=国产肝癌创新药多纳非尼一线治疗晚期肝细胞癌III期临床研究获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c1618553426)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594695, encodeId=6bd7159469503, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=RET突变型甲状腺髓样癌：selpercatinib的III期临床试验已开始, objectType=article, longId=185522, objectId=448618552283, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=448618552283, replyNumber=0, likeNumber=15, createdTime=2020-01-02, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=448618552283, moduleTitle=RET突变型甲状腺髓样癌：selpercatinib的III期临床试验已开始, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=448618552283)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594694, encodeId=d8ef159469428, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=三叶草生物制药在中国启动Etanercept生物类似物候选产品SCB-808的III期研究, objectType=article, longId=185519, objectId=938918551947, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=938918551947, replyNumber=0, likeNumber=74, createdTime=2020-01-02, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=938918551947, moduleTitle=三叶草生物制药在中国启动Etanercept生物类似物候选产品SCB-808的III期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=938918551947)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594693, encodeId=491f15946932a, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=痤疮治疗创新疗法Twyneo：达到了III期试验的主要终点, objectType=article, longId=185517, objectId=d8b718551ed7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8b718551ed7, replyNumber=0, likeNumber=59, createdTime=2020-01-02, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8b718551ed7, moduleTitle=痤疮治疗创新疗法Twyneo：达到了III期试验的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8b718551ed7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594692, encodeId=c5b91594692aa, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=Iterum Therapeutics宣布完成口服Sulopenem治疗尿道感染的III期临床试验注册, objectType=article, longId=185461, objectId=e368185461fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e368185461fe, replyNumber=0, likeNumber=14, createdTime=2020-01-01, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e368185461fe, moduleTitle=Iterum Therapeutics宣布完成口服Sulopenem治疗尿道感染的III期临床试验注册, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e368185461fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594691, encodeId=4ac71594691c8, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=JAMA Network Open：DAYVIGO（lemborexant）治疗失眠症的关键III期研究, objectType=article, longId=185379, objectId=6b761853e9f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b761853e9f9, replyNumber=0, likeNumber=83, createdTime=2019-12-30, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b761853e9f9, moduleTitle=JAMA Network Open：DAYVIGO（lemborexant）治疗失眠症的关键III期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b761853e9f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594690, encodeId=d4191594690c0, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=儿童造血干细胞移植相关的血栓性微血管病：Nomacopan关键性III期临床试验, objectType=article, longId=185186, objectId=397c185186ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=397c185186ea, replyNumber=0, likeNumber=18, createdTime=2019-12-26, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=397c185186ea, moduleTitle=儿童造血干细胞移植相关的血栓性微血管病：Nomacopan关键性III期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=397c185186ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594689, encodeId=d0091594689ac, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=PET成像剂PyL在前列腺癌的III期CONDOR试验中达到主要终点, objectType=article, longId=185152, objectId=4ea418515287, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ea418515287, replyNumber=0, likeNumber=62, createdTime=2019-12-26, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ea418515287, moduleTitle=PET成像剂PyL在前列腺癌的III期CONDOR试验中达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ea418515287)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1594688, encodeId=dc8c159468862, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, objectTitle=葛兰素史克宣布贝利尤单抗治疗狼疮性肾炎患者的III期临床试验取得整体阳性结果, objectType=article, longId=184997, objectId=556218499e7a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=556218499e7a, replyNumber=0, likeNumber=17, createdTime=2019-12-22, rootId=0, userName=智智灵药, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=556218499e7a, moduleTitle=葛兰素史克宣布贝利尤单抗治疗狼疮性肾炎患者的III期临床试验取得整体阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=556218499e7a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

III期

2020-05-29

智智灵药 (审核中...)

前往app查看评论内容

#III期#

JAK抑制剂baricitinib在III期特应性皮炎研究中显著改善皮肤炎症

2020-01-30

智智灵药 (审核中...)

前往app查看评论内容

#III期#

卡泊三醇喷雾剂治疗牛皮癣的III期临床取得阳性结果

2020-01-27

智智灵药 (审核中...)

前往app查看评论内容

#III期#

难治性晚期或复发性卵巢癌患者的III期试验：Opdivo（Nivolumab）未能改善总生存率

2020-01-27

智智灵药 (审核中...)

前往app查看评论内容

#III期#

传染性软疣的治疗：VP-102的III期CAMP试验取得阳性结果

2020-01-21

智智灵药 (审核中...)

前往app查看评论内容

#III期#

礼来宣布以11亿美元收购Dermira，同时获得中度至重度特应性皮炎III期IL-13单抗lebrikizumab

2020-01-18

智智灵药 (审核中...)

前往app查看评论内容

#III期#

NEJM的：诺华的IgE单抗Ligelizumab在慢性自发性荨麻疹的III期临床中完胜奥马珠单抗

2020-01-11

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Apellis的C3补体抑制剂Pegcetacoplan用于阵发性夜间血红蛋白尿的III期临床成功

2020-01-10

智智灵药 (审核中...)

前往app查看评论内容

#III期#

默沙东的Keytruda治疗小细胞肺癌的III期临床，未能明显改善患者的总体生存率

2020-01-10

智智灵药 (审核中...)

前往app查看评论内容

#III期#

默克和辉瑞的抗PD-L1单抗Bavencio改善了局部晚期或转移性尿路上皮癌患者的生存率：III期临床达到主要终点

2020-01-08

智智灵药 (审核中...)

前往app查看评论内容

#III期#

J Clin Oncol：III期试验：Ipilimumab辅助疗法与大剂量干扰素α-2b用于高风险黑色素瘤的优劣对比

2020-01-06

智智灵药 (审核中...)

前往app查看评论内容

#III期#

J Clin Oncol：III期试验：培美曲塞联合贝伐单抗作为NSCLC患者的维持疗法的有效性和安全性

2020-01-06

智智灵药 (审核中...)

前往app查看评论内容

#III期#

国产肝癌创新药多纳非尼一线治疗晚期肝细胞癌III期临床研究获得成功

2020-01-03

智智灵药 (审核中...)

前往app查看评论内容

#III期#

RET突变型甲状腺髓样癌：selpercatinib的III期临床试验已开始

2020-01-02

智智灵药 (审核中...)

前往app查看评论内容

#III期#

三叶草生物制药在中国启动Etanercept生物类似物候选产品SCB-808的III期研究

2020-01-02

智智灵药 (审核中...)

前往app查看评论内容

#III期#

痤疮治疗创新疗法Twyneo：达到了III期试验的主要终点

2020-01-02

智智灵药 (审核中...)

前往app查看评论内容

#III期#

Iterum Therapeutics宣布完成口服Sulopenem治疗尿道感染的III期临床试验注册

2020-01-01

智智灵药 (审核中...)

前往app查看评论内容

#III期#

JAMA Network Open：DAYVIGO（lemborexant）治疗失眠症的关键III期研究

2019-12-30

智智灵药 (审核中...)

前往app查看评论内容

#III期#

儿童造血干细胞移植相关的血栓性微血管病：Nomacopan关键性III期临床试验

2019-12-26

智智灵药 (审核中...)

前往app查看评论内容

#III期#

PET成像剂PyL在前列腺癌的III期CONDOR试验中达到主要终点

2019-12-26

智智灵药 (审核中...)

前往app查看评论内容

#III期#

葛兰素史克宣布贝利尤单抗治疗狼疮性肾炎患者的III期临床试验取得整体阳性结果

2019-12-22

科室
- - 订阅+
  - 更多科室
工具
服务